Qiagen (NYSE:QGEN – Get Free Report) and Prime Medicine (NYSE:PRME – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, analyst recommendations, risk, institutional ownership, profitability and earnings.
Institutional and Insider Ownership
70.0% of Qiagen shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 9.0% of Qiagen shares are held by insiders. Comparatively, 23.5% of Prime Medicine shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent ratings for Qiagen and Prime Medicine, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Qiagen | 0 | 5 | 4 | 0 | 2.44 |
| Prime Medicine | 0 | 0 | 9 | 1 | 3.10 |
Profitability
This table compares Qiagen and Prime Medicine’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Qiagen | 4.23% | 13.97% | 8.33% |
| Prime Medicine | N/A | -107.87% | -74.97% |
Volatility and Risk
Qiagen has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 1.86, meaning that its stock price is 86% more volatile than the S&P 500.
Earnings & Valuation
This table compares Qiagen and Prime Medicine”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Qiagen | $1.98 billion | 4.49 | $341.30 million | $0.36 | 111.52 |
| Prime Medicine | $800,000.00 | 490.21 | -$198.13 million | ($2.05) | -1.46 |
Qiagen has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.
Summary
Prime Medicine beats Qiagen on 8 of the 15 factors compared between the two stocks.
About Qiagen
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.
About Prime Medicine
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.
